Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adalimumab in active ulcerative colitis: a "real-life" observational study.
Italian Group for the Study of Inflammatory Bowel Disease; Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, Danese S, D'Incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Orlando A, Papparella LG, Renna S, Ricci C, Rizzello F, Sostegni R, Guidi L, Papi C. Italian Group for the Study of Inflammatory Bowel Disease, et al. Among authors: milla m. Dig Liver Dis. 2013 Sep;45(9):738-43. doi: 10.1016/j.dld.2013.03.018. Epub 2013 May 15. Dig Liver Dis. 2013. PMID: 23683530 Free article.
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.
Vultaggio A, Petroni G, Pratesi S, Nencini F, Cammelli D, Milla M, Prignano F, Annese V, Romagnani S, Maggi E, Matucci A; ABIRISK Consortium. Vultaggio A, et al. Among authors: milla m. Clin Exp Immunol. 2016 Dec;186(3):364-372. doi: 10.1111/cei.12858. Epub 2016 Oct 26. Clin Exp Immunol. 2016. PMID: 27569750 Free PMC article.
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Biancone L, et al. Among authors: milla m. Dig Liver Dis. 2017 Apr;49(4):338-358. doi: 10.1016/j.dld.2017.01.141. Epub 2017 Jan 17. Dig Liver Dis. 2017. PMID: 28161290
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.
Nencini F, Vultaggio A, Pratesi S, Cammelli D, Milla M, Fiori G, Bagnoli S, Prignano F, Romagnani S, Maggi E, Matucci A. Nencini F, et al. Among authors: milla m. J Allergy Clin Immunol Pract. 2018 Nov-Dec;6(6):2065-2072.e2. doi: 10.1016/j.jaip.2018.04.007. Epub 2018 Apr 13. J Allergy Clin Immunol Pract. 2018. PMID: 29660428
163 results